SEC Form 4 · accession 0001140361-18-019095
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
V Bryan Lawlis
Director
Period of report
Apr 17, 2018
Accepted (ET)
Apr 19, 2018 · 7:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 17, 2018 | M | 3,750 | $38.59 | A | 18,610 | D | |
| Common StockF1 | Apr 17, 2018 | S | 3,750 | $85.00 | D | 14,860 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy Common Stock)F1,F2 | $38.59 | Apr 17, 2018 | M | 3,750 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 3,750 | 0 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.
- F2Reflects the number of stock options outstanding after the transaction from this specific stock option grant.